Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 311 of the 333 references it cites were found in a registry or an index; 70 of the 272 sources its claims cite were checked for support.

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH

Open access
Svegliati-Baroni, Gianluca, Patrício, Bárbara, Lioci, Gessica, Macedo, Maria Paula, Gastaldelli, Amalia · 2020 · International Journal of Molecular Sciences

Abstract

Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease worldwide. Due to its association with obesity and diabetes and the fall in hepatitis C virus morbidity, cirrhosis in NAFLD is becoming the most frequent indication to liver transplantation, but the pathogenetic mechanisms are still not completely understood. The so-called gut-liver axis has gained enormous interest when data showed that its alteration can lead to NAFLD development and might favor the occurrence of non-alcoholic steatohepatitis (NASH). Moreover, several therapeutic approaches targeting the gut-pancreas-liver axis, e.g., incretins, showed promising results in NASH treatment. In this review, we describe the role of incretin hormones in NAFLD/NASH pathogenesis and treatment and how metagenomic/metabolomic alterations in the gut microbiota can lead to NASH in the presence of gut barrier modifications favoring the passage of bacteria or bacterial products in the portal circulation, i.e., bacterial translocation.

Overview

CoChat Summary

TL;DR

This review argues that the gut-pancreas-liver axis—incretin hormones, gut microbiota, bile acid signaling, and intestinal permeability—contributes to NAFLD/NASH pathogenesis and offers therapeutic targets. It summarizes evidence that GLP-1 receptor agonists, FXR agonists, and microbiota/permeability-directed approaches have variable benefits, with many human data still limited.

Key findings

  • NAFLD prevalence is estimated at about 25% in the general population, rising to 57% in those with BMI ≥30 kg/m², 70% in diabetic subjects, and 90% in morbidly obese patients undergoing metabolic surgery.
  • In the LEAN trial, 52 biopsy-proven NASH patients were randomized 1:1 to liraglutide 1.8 mg daily or placebo for 48 weeks; NASH resolution occurred in 39% vs 9%, and fewer liraglutide-treated patients showed fibrosis progression (2/23 vs 8/22).
  • In FLINT, obeticholic acid 25 mg/day for 72 weeks improved NAFLD activity score and decreased liver fibrosis, but NASH resolution occurred in only 22% of OCA patients without a statistically significant effect vs placebo; no effect was seen in advanced fibrosis, and pruritus developed in 23%. REGENERATE interim analysis at month 18 reported 23% (25 mg) and 18% (10 mg) vs 12% placebo meeting the primary endpoint of fibrosis improvement by at least one stage without NASH worsening.
  • A meta-analysis by Dong et al. including six GLP-1RA studies found reduced NASH activity (steatosis, lobular inflammation, hepatocyte ballooning) and fibrosis stage vs placebo; however, conclusive human data on GLP-1RA effects on hepatic fibrosis are lacking. Intestinal permeability was demonstrated in only 39% of NAFLD patients and 49% of NASH patients.

Methods

  • Narrative review; no primary data collection or systematic search is described. It synthesizes preclinical and clinical literature on incretins, DPP-4 inhibitors, GLP-1 co-agonists, gut microbiota, bile acids, and gut permeability in NAFLD/NASH.
  • Evidence discussed includes mouse models (ob/ob, db/db, high-fat diet, methionine/choline-deficient diet, diet-induced obesity), human randomized trials (e.g., LEAN, FLINT, REGENERATE), meta-analyses, and mechanistic studies.

Limitations

  • Stated: GLP-1RA studies often had limited patient numbers and lacked control groups; conclusive human data on GLP-1RA effects on hepatic fibrosis are lacking; no effective therapies directly targeting the gut-microbiota-liver axis exist; and there is no evidence that long-term gut bacterial composition change improves NAFLD/NASH in humans.
  • Stated: intestinal permeability assessment lacks a unique gold standard, and only 39% of NAFLD and 49% of NASH patients demonstrated permeability.
  • Evident: as a narrative review, it does not systematically appraise study quality or perform quantitative synthesis; conclusions rely heavily on animal models and small or heterogeneous human trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms21165820

Cites

311 of 311 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Secretion and physiological effects of incretin hormones GIP and GLP-1 in different organs and tissues. The intestinal epithelium is composed of several cell types, including enteroendocrine cells such as K-cells and L-cells, responsible for the secretion of GIP and GLP-1, respectively. The secretion of these hormones is triggered upon nutrient stimulation of G protein-coupled receptors (GPCRs) present in the cell membrane. Some of the nutrients responsible for GIP and GLP-1 secretion are glucose (and other carbohydrates), lipids, some amino acids and proteins. Bile acids can also stimulate incretin secretion. After secretion, GIP and GLP-1 exert their functions in the pancreas and extra-pancreatic tissues, such as the liver, adipose tissue, muscle, bone, and the central nervous system. Abbreviations: AA, Amino acids; CASR, Calcium-sensing receptor; FFAR, Free fatty acid receptor; GIP, Glucose-dependent insulinotropic peptide; GLP-1, Glucagon-like peptide-1; GLP-2, Glucagon-like peptide-2; GLUT, Glucose transporter; LCFA, Long-chain fatty acids; PYY, Peptide YY; SCFA, Short-chain fatty acids; SGLT, Sodium-dependent glucose cotransporter; TGR5, Takeda G protein-coupled receptor 5; VLDL, Very-low-density lipoprotein.
Figure 1 Secretion and physiological effects of incretin hormones GIP and GLP-1 in different organs and tissues. The intestinal epithelium is composed of several cell types, including enteroendocrine cells such as K-cells and L-cells, responsible for the secretion of GIP and GLP-1, respectively. The secretion of these hormones is triggered upon nutrient stimulation of G protein-coupled receptors (GPCRs) present in the cell membrane. Some of the nutrients responsible for GIP and GLP-1 secretion are glucose (and other carbohydrates), lipids, some amino acids and proteins. Bile acids can also stimulate incretin secretion. After secretion, GIP and GLP-1 exert their functions in the pancreas and extra-pancreatic tissues, such as the liver, adipose tissue, muscle, bone, and the central nervous system. Abbreviations: AA, Amino acids; CASR, Calcium-sensing receptor; FFAR, Free fatty acid receptor; GIP, Glucose-dependent insulinotropic peptide; GLP-1, Glucagon-like peptide-1; GLP-2, Glucagon-like peptide-2; GLUT, Glucose transporter; LCFA, Long-chain fatty acids; PYY, Peptide YY; SCFA, Short-chain fatty acids; SGLT, Sodium-dependent glucose cotransporter; TGR5, Takeda G protein-coupled receptor 5; VLDL, Very-low-density lipoprotein.CC BY · PubMed Central
Figure 2 Mechanistic effects of GLP-1 and GLP-1 receptor agonists in hepatic lipid metabolism. GLP-1 and GLP-1 receptor agonists act via G protein-coupled receptors (GPCRs) in hepatocytes to target several signaling pathways, resulting in increased β-oxidation in mitochondria, decreased hepatic mRNA expression of several lipogenic genes (SREBP1, FAS, ACC and SCD1), reduced de novo lipogenesis (DNL) and reduced steatosis. Abbreviations: ACC, Acetyl-CoA carboxylase α; ACOX, Peroxisomal acyl-coenzyme A oxidase; Akt, Serine/threonine protein kinase B/Akt; AMPK, 5′ AMP-activated protein kinase; ApoB, Apolipoprotein B 100; cAMP, Cyclic adenosine monophosphate; CPT1, Carnitine palmitoyltransferase 1; DNL, de novo lipogenesis; FAS, Fatty acid synthase; FFA, Free fatty acids; FGF21, Fibroblast growth factor 21; GLP-1, Glucagon-like peptide-1; GLP-1RA, Glucagon-like peptide-1 receptor agonists; GPCR, G-protein-coupled receptors; GSK-3, Glycogen synthase kinase 3; MTP, Microsomal triglyceride transfer protein; mTOR, mammalian target of rapamycin; PI3K, Phosphoinositide 3-kinase; PKA, Protein kinase A; PPAR, Peroxisome proliferator-activated receptor; SCD1, Stearoyl-CoA desaturase 1; Sirt1, Sirtuin 1; SREBP, Sterol regulatory element-binding protein; TCA, Tricarboxylic acid cycle; TG, Triglyceride; UPR, Unfolded protein response; VLDL, Very-low-density lipoprotein.
Figure 2 Mechanistic effects of GLP-1 and GLP-1 receptor agonists in hepatic lipid metabolism. GLP-1 and GLP-1 receptor agonists act via G protein-coupled receptors (GPCRs) in hepatocytes to target several signaling pathways, resulting in increased β-oxidation in mitochondria, decreased hepatic mRNA expression of several lipogenic genes (SREBP1, FAS, ACC and SCD1), reduced de novo lipogenesis (DNL) and reduced steatosis. Abbreviations: ACC, Acetyl-CoA carboxylase α; ACOX, Peroxisomal acyl-coenzyme A oxidase; Akt, Serine/threonine protein kinase B/Akt; AMPK, 5′ AMP-activated protein kinase; ApoB, Apolipoprotein B 100; cAMP, Cyclic adenosine monophosphate; CPT1, Carnitine palmitoyltransferase 1; DNL, de novo lipogenesis; FAS, Fatty acid synthase; FFA, Free fatty acids; FGF21, Fibroblast growth factor 21; GLP-1, Glucagon-like peptide-1; GLP-1RA, Glucagon-like peptide-1 receptor agonists; GPCR, G-protein-coupled receptors; GSK-3, Glycogen synthase kinase 3; MTP, Microsomal triglyceride transfer protein; mTOR, mammalian target of rapamycin; PI3K, Phosphoinositide 3-kinase; PKA, Protein kinase A; PPAR, Peroxisome proliferator-activated receptor; SCD1, Stearoyl-CoA desaturase 1; Sirt1, Sirtuin 1; SREBP, Sterol regulatory element-binding protein; TCA, Tricarboxylic acid cycle; TG, Triglyceride; UPR, Unfolded protein response; VLDL, Very-low-density lipoprotein.CC BY · PubMed Central
Figure 3 The gut-pancreas-liver axis in the context of non-alcoholic fatty liver disease (NAFLD). The intestine and the liver are in constant communication through the portal vein and the biliary tract. In the intestine, the maintenance of the intestinal endothelial cell barrier achieved through tight junctions is crucial. In pathological conditions, an alteration in the diversity and composition of gut microbiota could lead to the secretion of harmful bacterial products, which consequently damages the intestinal epithelium by disrupting tight junctions. Another mechanism that has been indicated to explain increased intestinal permeability is zonulin, a protein secreted within intestinal cells upon a trigger (e.g., gluten), which is thought to be responsible for tight junction disassembling. In such conditions, harmful bacteria/bacterial products cross the intestinal wall and reach the liver via portal circulation, where they activate toll-like receptors (TLRs) on hepatocyte cell surface, promoting steatosis, inflammation, apoptosis, and insulin resistance. The intestine is also responsible for the secretion of the incretin hormones GLP-1 and GIP upon nutrient stimulation, which go through the liver, reach circulation, and target the pancreas to regulate insulin and glucagon secretion. On the other hand, the liver secretes primary bile acids into the intestine to aid digestion, which are converted into secondary bile acids by gut microbiota, and the majority are reabsorbed back to the liver. A rearrangement in the gut-pancreas-liver axis has been hypothesized to play a role in the pathogenesis and development of NAFLD. Abbreviations: CD36, Cluster of differentiation 36; DNL, de novo lipogenesis; FFA, Free fatty acids; GIP, Glucose-dependent insulinotropic peptide; GLP-1, Glucagon-like peptide-1; IL, Interleukin; ROS, Reactive oxygen species; TAG, Triglycerides; TNF-α, Tumor necrosis factor α.
Figure 3 The gut-pancreas-liver axis in the context of non-alcoholic fatty liver disease (NAFLD). The intestine and the liver are in constant communication through the portal vein and the biliary tract. In the intestine, the maintenance of the intestinal endothelial cell barrier achieved through tight junctions is crucial. In pathological conditions, an alteration in the diversity and composition of gut microbiota could lead to the secretion of harmful bacterial products, which consequently damages the intestinal epithelium by disrupting tight junctions. Another mechanism that has been indicated to explain increased intestinal permeability is zonulin, a protein secreted within intestinal cells upon a trigger (e.g., gluten), which is thought to be responsible for tight junction disassembling. In such conditions, harmful bacteria/bacterial products cross the intestinal wall and reach the liver via portal circulation, where they activate toll-like receptors (TLRs) on hepatocyte cell surface, promoting steatosis, inflammation, apoptosis, and insulin resistance. The intestine is also responsible for the secretion of the incretin hormones GLP-1 and GIP upon nutrient stimulation, which go through the liver, reach circulation, and target the pancreas to regulate insulin and glucagon secretion. On the other hand, the liver secretes primary bile acids into the intestine to aid digestion, which are converted into secondary bile acids by gut microbiota, and the majority are reabsorbed back to the liver. A rearrangement in the gut-pancreas-liver axis has been hypothesized to play a role in the pathogenesis and development of NAFLD. Abbreviations: CD36, Cluster of differentiation 36; DNL, de novo lipogenesis; FFA, Free fatty acids; GIP, Glucose-dependent insulinotropic peptide; GLP-1, Glucagon-like peptide-1; IL, Interleukin; ROS, Reactive oxygen species; TAG, Triglycerides; TNF-α, Tumor necrosis factor α.CC BY · PubMed Central

Verification

Claims the paper makes

46 Valid · 8 Not valid · 138 Not checked · 28 Own results and interpretations

114 more claims · 27 with their cited sources checked

Create a free account to see all 220 claims and to verify the 202 references still open.

See all claims — free account
  • It may state two separate claims as one. 93
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 333 references

Research works printed but not linked: 2

  1. You, 2016, Long-Acting GLP-1 and Glucagon Receptor Dual Agonists for the Treatment of Type 2 Diabetes, Diabetes, 65, A221
  2. Hershkovitz, O., Bar-IIan, A., Hart, G., and Fima, E. (2013, January 15–18). The long-acting dual GLP-1/Glucagon Agonist, MOD-6030 improves glycaemic control and induces a prolonged weight loss in diet induced obesity mice following a once weekly administration. Proceedings of the Endocrine Society’s 95th Annual Meeting and Expo, San Francisco, CA, USA.

Cited by

Metadata

Authors
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A.
Affiliations
  • Liver Injury and Transplant Unit, Ospedali Riuniti Ancona, 60020 Ancona, Italy
  • Scuola Superiore Sant'Anna (IT)
  • Marche Polytechnic University (IT)
  • Associacao Protectora dos Diabeticos de Portugal (PT)
Corresponding author
  • Macedo, Maria Paula
  • Gastaldelli, Amalia
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-08-13
Volume
21
Issue
16
Pages
5820
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3048942363
Cited by
66
References
333
Citations by year
2026: 4 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 14 · 2021: 13
FWCI
1.42
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • H2020 Marie Skłodowska-Curie Actions (722619, 734719)
  • Consiglio Nazionale delle Ricerche (B54I19000370005)
  • Fundação para a Ciência e a Tecnologia (PTDC/BIM-MET/2115/2014, PTDC/MEC-MET/29314/2017)
  • iNOVA4Health (UID/Multi/04462/2013)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut-liver axis, incretins, gut microbiota, metagenomics, metabolomics, intestinal barrier dysfunction, bacterial translocation, NAFLD pathogenesis, NAFLD treatment
MeSH terms
Gastrointestinal Microbiome, Animals, Humans, Liver, Pancreas, Gastrointestinal Tract, Incretins, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.